NASDAQ: PCRXPacira Biosciences Inc Stock
$24.65+0.18 (+0.74%)
Updated Apr 17, 2025
PCRX Price
$24.65
Fair Value Price
N/A
Market Cap
$1.14B
52 Week Low
$11.16
52 Week High
$31.67
P/E
-11.47x
P/B
1.47x
P/S
1.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$700.97M
Earnings
-$99.56M
Gross Margin
75.7%
Operating Margin
-6.64%
Profit Margin
-14.2%
Debt to Equity
1
Operating Cash Flow
$189M
Beta
0.74
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PCRX Overview
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PCRX's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
PCRX
Ranked#2 of 54
Ranked#2 of 54
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.36 | A | |
| $13.76 | A | |
| $30.76 | A |
Be the first to know about important PCRX news, forecast changes, insider trades & much more!
PCRX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PCRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PCRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PCRX is good value based on its book value relative to its share price (1.47x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.99x)
P/B vs Industry Valuation
PCRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PCRX due diligence checks available for Premium users.
Valuation
PCRX fair value
Fair Value of PCRX stock based on Discounted Cash Flow (DCF)
Price
$24.65
Fair Value
$60.31
Undervalued by
59.13%
PCRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PCRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.47x
Industry
20.48x
Market
27.98x
PCRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.47x
Industry
1.99x
PCRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PCRX's financial health
Profit margin
Revenue
$187.3M
Net Income
$16.0M
Profit Margin
8.6%
PCRX's Earnings (EBIT) of -$46.54M... subscribe to Premium to read more.
Interest Coverage Financials
PCRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.6B
Liabilities
$775.2M
Debt to equity
1
PCRX's short-term assets ($745.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PCRX's short-term assets ($745.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PCRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PCRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$33.1M
Investing
-$368.0k
Financing
-$2.0M
PCRX's operating cash flow ($189.39M)... subscribe to Premium to read more.
Debt Coverage Financials
PCRX vs Pharmaceutical Stocks
Pacira Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.